GVK Biosciences (GVK BIO), the discovery research and development organisation based in Hyderabad, India, has reached a definitive agreement to acquire Aragen Bioscience, a preclinical contract research organisation operating out of Morgan Hill, US and specialising in high-value biologics services.
No financial terms were disclosed for the deal, in which GVK BIO is acquiring the capital stock of Aragen Bioscience. It is the Indian company’s first international acquisition.
According to a report in India’s Business Standard, GVK is taking a 65% stake in Aragen Biosciences and will acquire the remaining 35% over a period of two years, leaving Aragen to function as a separate entity.
Read more at: http://www.pharmatimes.com/Article/14-01-30/India_s_GVK_BIO_goes_international_with_Aragen_deal.aspx#ixzz2s3enmHuZ
Follow us: @PharmaTimes on Twitter
Filed under: COMPANIES Tagged: aragen, gvk bio
